NASDAQ:KRRO Korro Bio Q3 2026 Earnings Date & Estimates $16.44 +0.58 (+3.67%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more. Korro Bio is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 13, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 13, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Korro Bio in Q3 2026Korro Bio is expected to post earnings of -$1.2619 per share on revenue of $188 thousand. In the same quarter a year earlier Korro Bio reported -$1.92 per share on revenue of $1.09 million. Korro Bio last reported on August 6, 2026, posting -$1.07 per share and beating the -$1.34 consensus estimate. Korro Bio has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.2619Expected Revenue$188 thousandPrior-Year EPS-$1.92Prior-Year Revenue$1.09 millionExpected Revenue Growth-82.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.07 (Beat by +$0.27)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Korro Bio Q3 2026 Earnings FAQ When does Korro Bio report Q3 2026 earnings? Korro Bio (NASDAQ:KRRO) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Korro Bio's Q3 2026 earnings call? Korro Bio's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Korro Bio? Analysts expect Korro Bio to post earnings of -$1.2619 per share for Q3 2026. How much revenue is Korro Bio expected to report? The consensus revenue estimate for Korro Bio is $188 thousand for Q3 2026. Korro Bio Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Korro Bio (KRRO) and Spero Therapeutics (SPRO)October 30, 2026 | theglobeandmail.comKorro Bio (NASDAQ:KRRO) Stock: Insider Lynx1 Capital Management Lp Purchases 25,124 SharesOctober 28, 2026 | americanbankingnews.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.November 4 at 1:00 AM | Decentralized Masters (Ad)Korro Bio (NASDAQ:KRRO) Stock: Insider Lynx1 Capital Management Lp Purchases 52,175 SharesOctober 28, 2026 | americanbankingnews.comKorro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Buys 2,510 Shares of StockOctober 27, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Oric Pharmaceuticals (ORIC)October 25, 2026 | theglobeandmail.comSee More Korro Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email. Email Address About Korro BioKorro Bio (NASDAQ:KRRO) is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA. Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease. The program is intended to edit disease-associated RNA and promote production of functional alpha-1 antitrypsin protein. Founded in 2018 and headquartered in Cambridge, Massachusetts, Korro Bio conducts research and drug development in the United States. The company has focused on advancing its RNA editing platform and pipeline through preclinical and clinical development; it does not have a broadly marketed commercial product based on the information available.View Korro Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?Apple's Earnings Beat Comes With a Catch for Investors Heading Into the Holidays Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
